Femasys (NASDAQ:FEMY) Issues Quarterly Earnings Results

Femasys (NASDAQ:FEMY) issued its earnings results on Friday. The company reported ($0.53) EPS for the quarter, topping the consensus estimate of ($0.60) by $0.07, Zacks reports. The business had revenue of $0.40 million during the quarter, compared to the consensus estimate of $0.62 million. Femasys had a negative return on equity of 225.97% and a negative net margin of 534.36%.

Femasys Price Performance

NASDAQ:FEMY traded up $0.02 during trading hours on Friday, hitting $1.42. 52,887 shares of the company’s stock traded hands, compared to its average volume of 251,829. The firm has a market cap of $11.90 million, a P/E ratio of -0.40 and a beta of -2.13. Femasys has a 52 week low of $1.25 and a 52 week high of $20.80. The business’s fifty day simple moving average is $1.99 and its two-hundred day simple moving average is $5.67. The company has a quick ratio of 0.55, a current ratio of 2.14 and a debt-to-equity ratio of 0.89.

Wall Street Analyst Weigh In

A number of brokerages have recently issued reports on FEMY. Weiss Ratings downgraded shares of Femasys from a “sell (d-)” rating to a “sell (e+)” rating in a report on Monday, August 17th. Wall Street Zen lowered shares of Femasys from a “sell” rating to a “strong sell” rating in a research report on Sunday, November 8th. Lake Street Capital reduced their price objective on shares of Femasys to $10.00 and set a “buy” rating for the company in a research note on Tuesday, August 18th. Finally, Maxim Group decreased their target price on shares of Femasys to $10.00 and set a “buy” rating on the stock in a report on Friday, August 14th. Three investment analysts have rated the stock with a Buy rating and one has given a Sell rating to the company. Based on data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and a consensus price target of $50.00.

About Femasys

Femasys Inc. is a biotechnology and medical device company focused on developing and commercializing products for women’s health. The company’s portfolio is centered on solutions for permanent birth control, fertility evaluation and treatment, and related gynecological procedures. Femasys’ products include FemVue, a device used with saline and air to assess fallopian tube patency during fertility evaluations. The company is also developing FemBloc, a non-surgical, investigational permanent birth control system designed for placement through the fallopian tubes.